Skip to main content
Premium Trial:

Request an Annual Quote

Following Rally, Omics Tools and MDx Stocks Cool in February

NEW YORK (GenomeWeb News) – Following a run-up in the stock prices of many omics tools and molecular diagnostics firms at the beginning of 2013, investor enthusiasm cooled in February.

The GenomeWeb Daily News Index, which tracks the stocks of 30 companies operating in the molecular research tools and diagnostics fields, was nearly flat with January's close and failed to keep pace with the Dow Jones Industrial Average and Nasdaq Biotech Index, which both were up more than 1 percent, and the broader Nasdaq market, which gained .6 percent for the month of February.

Leading the gainers for the month was Accelerate Diagnostics, which closed up 22 percent for the month. Its shares have risen steadily since the beginning of the year despite any noticeable catalysts.

Bio-Rad Laboratories (+8 percent) and Affymetrix (+7 percent) posted the next biggest increases for February. Both Bio-Rad and Affy beat analysts' estimates on the top and bottom line for their fourth quarter results. Affymetrix also filed its CytoScan cytogenetics platform with the US Food and Drug Administration during the month.

Nanosphere led decliners for the month, dropping around 31 percent. In mid-February the firm reported that its full-year revenues more than doubled as it trimmed its annual loss, and it named a new CEO and replaced several board members, sending its shares tumbling.

Other firms in the GWDN Index that saw a double-digit drop during the month were CombiMatrix (-24 percent) and Life Technologies (-10 percent). Shares of Life Tech declined after reports during the month threw cold water on a potential acquisition of leveraged buyput of the firm.


The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.